.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKesson
Chubb
US Department of Justice
Federal Trade Commission
Covington
Boehringer Ingelheim
Medtronic
Citi
Dow

Generated: November 21, 2017

DrugPatentWatch Database Preview

Plerixafor - Generic Drug Details

« Back to Dashboard

What are the generic sources for plerixafor and what is the scope of plerixafor patent protection?

Plerixafor
is the generic ingredient in one branded drug marketed by Genzyme and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Plerixafor has seventy-two patent family members in twenty-nine countries and seventeen supplementary protection certificates in twelve countries.

There are five drug master file entries for plerixafor. Two suppliers are listed for this compound.

Pharmacology for plerixafor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: plerixafor

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: plerixafor

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,750Methods to mobilize progenitor/stem cells► Subscribe
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity► Subscribe
7,935,692Methods to mobilize progenitor/stem cells► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: plerixafor

Country Document Number Estimated Expiration
Spain2380009► Subscribe
European Patent Office1223166► Subscribe
Australia661086► Subscribe
World Intellectual Property Organization (WIPO)03011277► Subscribe
South Korea20040020075► Subscribe
MexicoPA04000982► Subscribe
Poland364673► Subscribe
China102302493► Subscribe
United Kingdom9126677► Subscribe
World Intellectual Property Organization (WIPO)9312096► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PLERIXAFOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0120014 00064Estonia► SubscribePRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009
00537Netherlands► SubscribePRODUCT NAME: PLERIXAFOR IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
2009 00052Denmark► Subscribe
/2012Austria► SubscribePRODUCT NAME: PLERIXAFOR, GEGEBENENFALLS ALS PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
2012000044Germany► SubscribePRODUCT NAME: PLERIXAFOR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER EIN METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
C/GB12/031United Kingdom► SubscribePRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804
C038/2009Ireland► SubscribeSPC038/2009: 20101001, EXPIRES: 20171215
90023-9Sweden► SubscribePRODUCT NAME: PLERIXAFOR, VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/09/534/001 20090804
2012011Lithuania► SubscribePRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
033Luxembourg► Subscribe92033, EXPIRES: 20240731
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Cerilliant
US Department of Justice
Express Scripts
Daiichi Sankyo
Accenture
McKesson
Fish and Richardson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot